Notices. Notice with request for comments

2,340 words·~11 min read·/register/2015/07/17/2015-17561·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-420N] Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016 AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Notice with request for comments. SUMMARY: The Drug Enforcement Administration proposes to establish the 2016 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: Interested persons may file written comments on or objections to this notice in accordance with 21 CFR 1303.11(c) and 1315.11(d). Electronic comments must be submitted, and written comments must be postmarked, on or before August 17, 2015. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. The Administrator may hold a public hearing on one or more issues raised by the comments received in response to this notice.

In the event the Administrator decides in his sole discretion to hold such a hearing, the Administrator will publish a notice of any such hearing in the **Federal Register** . After consideration of any comments and after a hearing, if one is held, the Administrator will publish in the **Federal Register** a final order establishing the 2016 aggregate production quotas for schedule I and II controlled substances, and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

ADDRESSES: To ensure proper handling of comments, please reference “Docket No. DEA-420N” on all correspondence, including any attachments. The Drug Enforcement Administration encourages that all comments be submitted electronically through the Federal eRulemaking Portal which provides the ability to type short comments directly into the comment field on the Web page or attach a file for lengthier comments. Please go to *http://www.regulations.gov* and follow the online instructions at that site for submitting comments.

Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on Regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. Paper comments that duplicate electronic submissions are not necessary and are discouraged. Should you wish to mail a paper comment *in lieu* of an electronic comment, it should be sent via regular or express mail to:

Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/ODL, 8701 Morrissette Drive, Springfield, Virginia 22152. FOR FURTHER INFORMATION CONTACT: John R. Scherbenske, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone:

(202)598-6812. SUPPLEMENTARY INFORMATION: Posting of Public Comments Please note that all comments received in response to this docket are considered part of the public record. They will, unless reasonable cause is given, be made available for public inspection online at *http://www.regulations.gov.* Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter. The Freedom of Information Act applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase “PERSONAL IDENTIFYING INFORMATION” in the first paragraph of your comment. You must also place all the personal identifying information you do not want publicly available in the first paragraph of your comment and identify what information you want redacted. If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase “CONFIDENTIAL BUSINESS INFORMATION” in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. Comments containing personal identifying information or confidential business information identified and located as directed above will generally be made available in redacted form. If a comment contains so much personal identifying information or confidential business information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to *http://www.regulations.gov* may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as personal. An electronic copy of this document is available at *http://www.regulations.gov* for easy reference. Legal Authority The Drug Enforcement Administration

(DEA)implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. 21 U.S.C. 801-971. Titles II and III are referred to as the “Controlled Substances Act” and the “Controlled Substances Import and Export Act,” respectively, and are collectively referred to as the “Controlled Substances Act” or the “CSA” for the purpose of this action. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while ensuring an adequate supply is available for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and to establish the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the DEA pursuant to 28 CFR 0.100. Analysis for Proposed 2016 Aggregate Production Quotas and Assessment of Annual Needs The proposed year 2016 aggregate production quotas and assessment of annual needs represent those quantities of schedule I and II controlled substances, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured in the United States in 2016 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These proposals include estimated imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include estimated imports of controlled substances for use in industrial processes. In determining the proposed 2016 aggregate production quotas and assessment of annual needs, the Administrator has taken into account the criteria that is required to be considered in accordance with 21 U.S.C. 826(a), 21 CFR 1303.11 (aggregate production quotas for controlled substances), and 21 CFR 1315.11 (assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine). The Administrator estimates the aggregate production quotas and assessment of annual needs for 2016 by considering the following factors:

(1)Total net disposal of each class or chemical by all manufacturers and chemical importers during the current and two preceding years;

(2)trends in the national rate of net disposal of the class or chemical;

(3)total actual (or estimated) inventories of the class or chemical and of all substances manufactured from the class or chemical, and trends in inventory accumulation;

(4)projected demand for each class or chemical as indicated by procurement and chemical import quotas requested in accordance with 21 CFR 1303.12, 1315.32, and 1315.34; and

(5)other factors affecting the medical, scientific, research, and industrial needs of the United States, lawful export requirements, and reserve stocks, as the Administrator finds relevant. Other factors the Administrator considered in calculating the aggregate production quotas, but not the assessment of annual needs, include product development requirements of both bulk and finished dosage form manufacturers, and other pertinent information. In determining the proposed 2016 assessment of annual needs, the DEA used the calculation methodology previously described in the 2010 and 2011 assessments of annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR 79407, Dec. 20, 2010, respectively). The Administrator also specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. *See* 21 CFR 1303.24. This would be of concern if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, the Administrator proposes to include in all schedule II aggregate production quotas, and certain schedule I aggregate production quotas (difenoxin, gamma-hydroxybutyric acid, and tetrahydrocannabinols), an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The proposed aggregate production quotas reflect these included amounts. This action will not affect the ability of manufacturers to maintain inventory allowances as specified by regulation. The Administrator expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event results in substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by the Administrator. The Administrator does not anticipate utilizing the reserve in the absence of these circumstances. The Administrator, therefore, proposes to establish the 2016 aggregate production quotas for the following basic classes of schedule I and II controlled substances and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Basic class Proposed 2016 quotas

(g)Schedule I (1-Pentyl-1 *H* -indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) 25 [1-(5-Fluoro-pentyl)-1 *H* -indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) 25 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) 15 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) 25 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) 25 1-(1-Phenylcyclohexyl)pyrrolidine 10 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) 45 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) 45 1-[1-(2-Thienyl)cyclohexyl]piperidine 15 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) 45 1-Butyl-3-(1-naphthoyl)indole (JWH-073) 45 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) 45 1-Hexyl-3-(1-naphthoyl)indole (JWH-019) 45 1-Methyl-4-phenyl-4-propionoxypiperidine 2 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) 45 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) 45 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) 45 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) 45 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) 45 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) 45 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) 45 2-(2,5-Dimethoxy-4- *n* -propylphenyl)ethanamine (2C-P) 30 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 30 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) 30 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) 30 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 30 2-(4-Bromo-2,5-dimethoxyphenyl)- *N* -(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) 25 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) 30 2-(4-Chloro-2,5-dimethoxyphenyl)- *N* -(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) 25 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) 30 2-(4-Iodo-2,5-dimethoxyphenyl)- *N* -(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) 15 2-(Methylamino)-1-phenylpentan-1-one (pentedrone) 25 2,5-Dimethoxy-4-ethylamphetamine

(DOET)25 2,5-Dimethoxy-4- *n* -propylthiophenethylamine 25 2,5-Dimethoxyamphetamine 25 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) 30 3,4,5-Trimethoxyamphetamine 25 3,4-Methylenedioxyamphetamine

(MDA)55 3,4-Methylenedioxymethamphetamine

(MDMA)50 3,4-Methylenedioxy- *N* -ethylamphetamine

(MDEA)40 3,4-Methylenedioxy- *N* -methylcathinone (methylone) 50 3,4-Methylenedioxypyrovalerone

(MDPV)35 3-Fluoro- *N* -methylcathinone (3-FMC) 25 3-Methylfentanyl 2 3-Methylthiofentanyl 2 4-Bromo-2,5-dimethoxyamphetamine

(DOB)25 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) 25 4-Fluoro- *N* -methylcathinone (4-FMC) 25 4-Methoxyamphetamine 150 4-Methyl-2,5-dimethoxyamphetamine

(DOM)25 4-Methylaminorex 25 4-Methyl- *N* -ethylcathinone (4-MEC) 25 4-Methyl- *N* -methylcathinone (mephedrone) 45 4-Methyl-α-pyrrolidinopropiophenone (4-MePPP) 25 5-(1,1-Dimethylheptyl)-2-[(1 *R,* 3 *S* )-3-hydroxycyclohexyl]-phenol 68 5-(1,1-Dimethyloctyl)-2-[(1 *R,* 3 *S* )-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) 53 5-Methoxy-3,4-methylenedioxyamphetamine 25 5-Methoxy- *N,N* -diisopropyltryptamine 25 5-Methoxy- *N,N* -dimethyltryptamine 25 Acetyl- *alpha* -methylfentanyl 2 Acetyldihydrocodeine 2 Acetylmethadol 2 Allylprodine 2 Alphacetylmethadol 2 *alpha* -Ethyltryptamine 25 Alphameprodine 2 Alphamethadol 2 *alpha* -Methylfentanyl 2 *alpha* -Methylthiofentanyl 2 *alpha* -Methyltryptamine

(AMT)25 *alpha* -Pyrrolidinobutiophenone (α-PBP) 25 *alpha* -Pyrrolidinopentiophenone (α-PVP) 25 Aminorex 25 Benzylmorphine 2 Betacetylmethadol 2 *beta* -Hydroxy-3-methylfentanyl 2 *beta* -Hydroxyfentanyl 2 Betameprodine 2 Betamethadol 4 Betaprodine 2 Bufotenine 3 Cathinone 70 Codeine methylbromide 5 Codeine- *N* -oxide 305 Desomorphine 25 Diethyltryptamine 25 Difenoxin 11,000 Dihydromorphine 3,000,000 Dimethyltryptamine 35 Dipipanone 5 Fenethylline 5 *gamma* -Hydroxybutyric acid 70,250,000 Heroin 50 Hydromorphinol 2 Hydroxypethidine 2 Ibogaine 5 Lysergic acid diethylamide

(LSD)40 Marihuana 200,000 Mescaline 25 Methaqualone 10 Methcathinone 25 Methyldesorphine 5 Methyldihydromorphine 2 Morphine methylbromide 5 Morphine methylsulfonate 5 Morphine- *N* -oxide 350 *N* -(1-Adamantyl)-1-pentyl-1 *H* -indazole-3-carboxamide (AKB48) 25 *N* -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 *H* -indazole-3-carboxamide (ADB-PINACA) 25 *N* -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 *H* -indazole-3-carboxamide (AB-FUBINACA) 25 *N* -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 *H* -indazole-3-carboxamide (AB-CHMINACA) 15 *N* -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1 *H* -indazole-3-carboxamide (AB-PINACA) 15 *N,N* -Dimethylamphetamine 25 Naphthylpyrovalerone (naphyrone) 25 *N* -Benzylpiperazine 25 *N* -Ethyl-1-phenylcyclohexylamine 5 *N* -Ethylamphetamine 24 *N* -Hydroxy-3,4-methylenedioxyamphetamine 24 Noracymethadol 2 Norlevorphanol 52 Normethadone 2 Normorphine 40 Para-fluorofentanyl 5 Parahexyl 5 Phenomorphan 2 Pholcodine 5 Psilocybin 30 Psilocyn 50 Quinolin-8-yl 1-(5-fluoropentyl)-1 *H* -indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) 25 Quinolin-8-yl 1-pentyl-1 *H* -indole-3-carboxylate (PB-22; QUPIC) 25 Tetrahydrocannabinols 511,250 Thiofentanyl 2 Tilidine 25 Trimeperidine 2 Schedule II 1-Phenylcyclohexylamine 5 1-Piperidinocyclohexanecarbonitrile 5 4-Anilino- *N* -phenethyl-4-piperidine

(ANPP)2,950,000 Alfentanil 17,750 Alphaprodine 3 Amobarbital 25,125 Amphetamine (for conversion) 15,000,000 Amphetamine (for sale) 37,500,000 Carfentanil 19 Cocaine 200,000 Codeine (for conversion) 50,000,000 Codeine (for sale) 63,900,000 Dextropropoxyphene 45 Dihydrocodeine 226,375 Diphenoxylate (for conversion) 31,250 Diphenoxylate (for sale) 1,337,500 Ecgonine 125,000 Ethylmorphine 3 Fentanyl 2,300,000 Glutethimide 3 Hydrocodone (for conversion) 235,000 Hydrocodone (for sale) 88,500,000 Hydromorphone 7,000,000 Isomethadone 5 Levo-alphacetylmethadol

(LAAM)4 Levomethorphan 30 Levorphanol 7,125 Lisdexamfetamine 29,750,000 Meperidine 5,450,000 Meperidine Intermediate-A 6 Meperidine Intermediate-B 11 Meperidine Intermediate-C 6 Metazocine 19 Methadone (for sale) 31,875,000 Methadone Intermediate 34,375,000 Methamphetamine 2,061,375 [1,250,000 grams of *levo* -desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)] Methylphenidate 87,500,000 Morphine (for conversion) 91,250,000 Morphine (for sale) 62,500,000 Nabilone 18,750 Noroxymorphone (for conversion) 17,500,000 Noroxymorphone (for sale) 1,475,000 Opium (powder) 112,500 Opium (tincture) 687,500 Oripavine 30,000,000 Oxycodone (for conversion) 6,250,000 Oxycodone (for sale) 139,150,000 Oxymorphone (for conversion) 29,000,000 Oxymorphone (for sale) 7,750,000 Pentobarbital 38,125,000 Phenazocine 6 Phencyclidine 50 Phenmetrazine 3 Phenylacetone 50 Racemethorphan 3 Remifentanil 3,750 Secobarbital 215,003 Sufentanil 6,255 Tapentadol 25,500,000 Thebaine 125,000,000 List I Chemicals Ephedrine (for conversion) 100,000 Ephedrine (for sale) 4,000,000 Phenylpropanolamine (for conversion) 22,400,000 Phenylpropanolamine (for sale) 8,500,000 Pseudoephedrine (for conversion) 7,000 Pseudoephedrine (for sale) 224,500,000 The Administrator further proposes that the aggregate production quotas for all other basic classes of schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Administrator may adjust the 2016 aggregate production quotas and assessment of annual needs as necessary. Dated: July 13, 2015. Chuck Rosenberg, Acting Administrator. [FR Doc. 2015-17561 Filed 7-16-15; 8:45 am]

Connectionstraces to 8

Traces to 8 documents

CFR